Characterization of Optimized Functional-Complementary Dual Insulinotorpic Peptide rolGG

Area of Science:

• Endocrinology
• Molecular Biology
• Biochemistry

Background:

• Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are crucial for glucose regulation in islet beta-cells.
• These incretin hormones exhibit complementary physiological roles.
• Developing novel therapeutic agents targeting these pathways is essential for managing type 2 diabetes.

Purpose of the Study:

• To engineer a fusion peptide, 4rolGG, by linking four tandem repeats of GLP-1 and GIP.
• To evaluate the therapeutic efficacy of 4rolGG in a mouse model of type 2 diabetes.

Main Methods:

• Construction and high-level expression of the 4rolGG fusion peptide in BL21 (DE3) using IPTG induction.
• Confirmation of expression via SDS-PAGE electrophoresis and Western Blotting.
• Purification of 4rolGG using Ni-NTA affinity chromatography, achieving over 90% purity.

Main Results:

• Oral administration of 4rolGG for four weeks led to significant reductions in plasma glucose levels in diabetic mice.
• Key glycemic control markers, including HbA1c, total cholesterol (TC), and triglycerides (TG), were markedly decreased.
• Insulin levels were significantly elevated following 4rolGG treatment.

Conclusions:

• The 4rolGG fusion peptide demonstrates potent therapeutic potential for type 2 diabetes.
• This novel peptide effectively improves glucose homeostasis and lipid profiles.
• 4rolGG represents a promising candidate for further investigation as a diabetes treatment.